Why Is Ligand Pharmaceuticals Stock Trading Higher Today?



Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported fourth-quarter 2023 sales of $28.1 million, beating the consensus of $25.72 million

Revenues for the same period in 2022, excluding sales related to COVID-19, were $26.8 million

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022. 

Core Captisol sales (excluding sales of Captisol related to COVID-19) were $3.9 million compared with $3.3 million a year ago. 

There were no Captisol sales related to treatments for COVID-19 for the fourth quarter of 2023, compared with $23.5 million in the fourth quarter of 2022. Contract revenue was …

Full story available on Benzinga.com


Leave a Reply

Your email address will not be published. Required fields are marked *